MRK: financial statements from SEC — TradeAlmanac

MRK

Merck & Company, Inc. Common Stock (new): financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Revenue	16.29bn	17.28bn	15.81bn	15.53bn	16.66bn	16.11bn
Cost of revenue	4.20bn	3.86bn	3.56bn	3.42bn	4.08bn	3.75bn
Research and development	12.59bn	4.23bn	4.05bn	3.62bn	5.86bn	3.50bn
Selling, general and administrative	2.70bn	2.63bn	2.65bn	2.55bn	2.73bn	2.74bn
Pre-tax income	−3.53bn	6.75bn	5.00bn	5.90bn	4.09bn	6.01bn
Income tax	709m	958m	571m	818m	929m	545m
Net income	−4.24bn	5.79bn	4.43bn	5.08bn	3.16bn	5.46bn
Earnings per share	−1.72	2.32	1.76	2.01	1.25	2.15
Earnings per share, diluted	−1.72	2.32	1.76	2.01	1.24	2.14

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	5.33bn	14.57bn	18.17bn	8.01bn	8.63bn	13.24bn	14.69bn	11.37bn
Short-term investments	375m	0

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	3.92bn	2.50bn
Depreciation and amortisation	581m	502m
Share-based compensation	185m	195m
Capital expenditure	991m	1.33bn
Investing cash flow	−10.21bn	−1.49bn
Dividends paid	2.11bn

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)